Faith L. Charles - 18 Dec 2024 Form 4 Insider Report for CONDUIT PHARMACEUTICALS INC. (CDT)

Reporting relationship: Director
Issuer ticker: CDT
Reported as of: 18 Dec 2024
Net transaction value: +$29,820
SEC form: 4
Accepted by SEC: 20 Dec 2024, 17:06:31 UTC
Prior SEC filing: 20 Nov 2024
Next SEC filing: 03 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Faith L. Charles

Key filing fact

Faith L. Charles filed Form 4 for CONDUIT PHARMACEUTICALS INC. (CDT) on 20 Dec 2024.

Key facts

This page summarizes Faith L. Charles's Form 4 filing for CONDUIT PHARMACEUTICALS INC. (CDT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Dec 2024, 17:06.

Change

Previous filing in this sequence was filed on 20 Nov 2024.
Current net transaction value: +$29,820.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CDT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $29,820
Shares: +420,000
Change %
Price: $0.0710
Shares after: 420,000
Date: 18 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 420,000
Exercise price: $0.0710
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan, which were granted at the conclusion of the Issuer's 2024 annual meeting of stockholders.

Footnote F2

The options will vest on the earlier of (x) the first anniversary of the date of grant, or (y) the date immediately prior to the next annual meeting of the Issuer's stockholders following the date of grant.